Category: Minimally Invasive Surgery

Intuitive Surgical inks pact, buys 3% of Cardica

August 18, 2010 by MassDevice staff

Intuitive Surgical Inc. (NSDQ:ISRG) and Cardica Inc. (NSDQ:CRDC) agreed to integrate Cardica's micro-cutter technology for Intuitive's da Vinci robotic surgery system and for Intuitive to pick up a 3 percent stake in Cardica.

NxThera lands $1 million in funding for prostate device

August 4, 2010 by MedCity News

NxThera Inc. raised $1 million from the sale of debt and convertible notes according to a U.S. Securities and Exchange Commission filing.

The St. Paul, Minn.-based start-up is developing ways to treat enlarged prostates by using vapor injections and thermal energy to kill tissue.

Covidien wins reversal of Becton Dickinson needle patents suit

July 30, 2010 by MassDevice staff

Covidien Plc. (NYSE:COV) won an appeal of a trial judge's decision to back Becton Dickinson and Company's (NYSE:BDX) patent infringement claim.

The U.S. Court of Appeals for the Federal Circuit in Washington on Thursday tossed the $58 million damage award against the Mansfield, Mass. based medical products conglomerate, formerly Tyco Healthcare, over safety syringes.

Intuitive Surgical's Q2 results beat everything - except future expectations

July 22, 2010 by MassDevice staff

Intuitive Surgical Inc. (NSDQ:ISRG) crushed year-ago comparisons and blew through analyst expectations for the quarter, posting a $89 million profit during the three months ended June 30 on $351 million in revenues.

But in the "What have you done for me lately?" category, shares of the Sunnyvale, Calif.-based maker of robotic surgical tools were taking a pounding in after-market trading July 21 — falling nearly 8 percent at one point — after Intuitive executives didn't raise their revenue forecast as much as Wall Street had hoped.

Citi analyst: Covidien is the top stock pick for 2010

December 22, 2009 by MassDevice staff

A spate of mid-tier acquisitions, culminating in the recent Aspect Medical Systems buyout, has Covidien (NYSE:COV) poised for big gains on Wall Street next year, according to a Citi Investment Research analyst who made the company's stock his top pick for 2010.

Analyst Matthew Dodds, who covers health care and equipment supplies for Citi, said he expects shares of Covidien stock to rise to around $56 per share, a 20 percent premium on yesterday's $47-per-share closing price.

Hologic wins FDA nod for MammoSite ML radiation therapy system

September 1, 2009 by MassDevice staff

Hologic Inc. landed 510(k) approval from the Food & Drug Administration for its MammoSite ML radiation therapy system, saying it plans to bring the device to market during the first quarter of fiscal 2010, which begins in October.

The Bedford, Mass.-based women's health products maker said the device's multi-lumen design gives radiation oncologists the ability to shape the dose for breast cancer patients, delivering targeted radiation therapy directly to the area where cancer is most likely to recur.